Fluid therapy with specific mucopolysaccharides. A new approach to control diarrhea.
An evaluation is given of the shortcomings of existing oral fluid therapies and their consequences: lack of protection of the intestinal wall and the supply of unabsorbed carbohydrates to the large intestine. The inclusion of specific mucopolysaccharides having a polyxylose backbone and galactose end residues in the side chains seems to offer effective protection of the intestinal wall. A trial conducted in experimentally infected calves (E. coli) shows that this concept of oral fluid therapy limits the number of diarrhea days and induces better growth in calves; a more complete glucose absorption and limitation of the supply of unabsorbed carbohydrates to the large intestine was shown in a trial conducted in human patients with a rotavirus enteritis.
Verschoor
J
J
Research and Development Division, Pharmalett International BV, Made, The Netherlands.
Christensen
C R
CR
D000818:Animals; D000831:Animals, Newborn; D002417:Cattle; D002418:Cattle Diseases / Q000628:therapy*; D003967:Diarrhea / Q000628:therapy / Q000662:veterinary*; D005440:Fluid Therapy / Q000662:veterinary*; D006025:Glycosaminoglycans / Q000627:therapeutic use*; D006801:Humans
D006025:Glycosaminoglycans